Stock A048410 HYUNDAI BIOSCIENCE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Hyundai Bioscience Co., Ltd. Stock

Equities

A048410

KR7048410005

Personal Products

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
20,300 KRW +3.89% Intraday chart for Hyundai Bioscience Co., Ltd. +1.25% -22.22%
May. 20 Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd.. CI
May. 16 Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Financials

Sales 2022 7.85B 5.67M Sales 2023 9.48B 6.85M Capitalization 1,039B 750M
Net income 2022 -15.81B -11.41M Net income 2023 -14.5B -10.47M EV / Sales 2022 137 x
Net cash position 2022 12.48B 9.01M Net cash position 2023 6.27B 4.52M EV / Sales 2023 109 x
P/E ratio 2022
-68.2 x
P/E ratio 2023
-71.5 x
Employees 63
Yield 2022 *
-
Yield 2023
-
Free-Float 87.08%
More Fundamentals * Assessed data

Chart Hyundai Bioscience Co., Ltd.

Dynamic Chart

Latest news about Hyundai Bioscience Co., Ltd.

Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd.. CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 18 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI
Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil CI
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer CI
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer CI
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection CI
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion. CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vector Inc. completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Vector Inc. agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. for KRW 13.7 billion. CI
More news

Quotes and Performance

1 day+3.89%
1 week+1.25%
1 month+0.25%
3 months-1.69%
6 months-30.12%
Current year-22.22%
More quotes

Highs and lows

1 week
19 150.00
Extreme 19150
20 400.00
1 month
19 150.00
Extreme 19150
21 750.00
Current year
17 600.00
Extreme 17600
26 350.00
1 year
17 600.00
Extreme 17600
41 200.00
3 years
17 600.00
Extreme 17600
41 600.00
5 years
6 310.00
Extreme 6310
66 300.00
10 years
1 820.00
Extreme 1820
66 300.00
More quotes

Managers and Directors - Hyundai Bioscience Co., Ltd.

Managers TitleAgeSince
Sang-Gi Oh CEO
 Chief Executive Officer 64 13-03-28
Kwang-Hee Kim PRN
 Corporate Officer/Principal 58 -
Yeong-Kwon Jeong PRN
 Corporate Officer/Principal 57 -
Members of the board TitleAgeSince
Sang-Gi Oh CEO
 Chief Executive Officer 64 13-03-28
Yeong-Kwon Jeong PRN
 Corporate Officer/Principal 57 -
More insiders

ETFs positioned on Hyundai Bioscience Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
DEMOCRACY INTERNATIONAL FUND ETF - USD ETF Democracy International Fund ETF - USD
0.00% 7 M€ +5.36% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 112 M€ +4.61% -
More ETFs positioned on Hyundai Bioscience Co., Ltd.

Quotes

Date Price Change Volume
24-05-31 20,300 +3.89% 267,928
24-05-30 19,540 +0.05% 208,177
24-05-29 19,530 -2.35% 233,849
24-05-28 20,000 -.--% 209,304
24-05-27 20,000 -0.25% 193,518

End-of-day quote Korea S.E., May 30, 2024

More quotes

Company Profile

HYUNDAI BIOSCIENCE CO., LTD. it is a Korea-based company mainly engaged in the manufacturing and sale of bio cosmetics and hair tonic products. It develops functional daily necessities such as shampoos, mask packs, creams, and tumor-targeted drug. The Company also sells liquid crystal display (LCD) monitors and digital signage display products. The Company distributes its products in domestic market, as well as to the overseas markets, including Europe, America and Japan.
Sector
Personal Products
Calendar
2024-08-12 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Personal Products

1st Jan change Capi.
HYUNDAI BIOSCIENCE CO., LTD. Stock Hyundai Bioscience Co., Ltd.
-22.22% 584M
PROCTER & GAMBLE COMPANY Stock Procter & Gamble Company
+12.28% 388B
UNILEVER PLC Stock Unilever PLC
+12.61% 136B
COLGATE-PALMOLIVE COMPANY Stock Colgate-Palmolive Company
+16.62% 76.27B
HINDUSTAN UNILEVER LIMITED Stock Hindustan Unilever Limited
-12.57% 65.56B
ESTEE LAUDER Stock Estee Lauder
-15.65% 44.23B
KENVUE INC. Stock Kenvue Inc.
-10.36% 36.96B
BEIERSDORF Stock Beiersdorf
+6.37% 35.04B
ESSITY AB Stock Essity AB
+7.80% 18.02B
GODREJ CONSUMER PRODUCTS LIMITED Stock Godrej Consumer Products Limited
+12.30% 15.57B
Other Personal Products
  1. Stock Market
  2. Equities
  3. A048410 Stock